HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Tuesday, 23 September 2014

Recently published CEAs

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers.  From the ones listed this time, here's a few in our areas of research interest:

Graham CN, Hechmati G, Hjelmgren J, et. al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Sep 11. [Epub ahead of print] PubMed PMID: 25219451.
Image by the Italian voice via Flickr CC BY 2.0

Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2014 Sep 15. [Epub ahead of print] PubMed PMID: 25219291.

Kiadaliri AA, Gerdtham UG, Eliasson B, et. al. Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes Ther. 2014 Sep 12. [Epub ahead of print] PubMed PMID: 25213800.

Seguí MA, Crespo C, Cortés J, et. al. Genomic profile of breast cancer: cost-effectiveness analysis from the  Spanish National Healthcare System perspective.Expert Rev Pharmacoecon Outcomes Res. 2014 Sep 12:1-11. [Epub ahead of print] PubMed PMID: 25213317.
Posted by at
Labels: